Medicines Company’s inclisiran meets all endpoints in ORION-10 trial

European Commission grants orphan drug status to SpringWorks’ desmoid tumours drug. Credit: Dimitris Vetsikas from Pixabay.



  • SpringWorks gets orphan status for nirogacestat in Europe